Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.

Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R.

Clin Cancer Res. 2006 Dec 15;12(24):7261-70. Review.

2.

PI3 kinases in cancer: from oncogene artifact to leading cancer target.

Zhao JJ, Roberts TM.

Sci STKE. 2006 Dec 12;2006(365):pe52.

PMID:
17164467
3.

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, Workman P.

Bioorg Med Chem. 2007 Jan 1;15(1):403-12. Epub 2006 Oct 16.

PMID:
17049248
4.

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

Corradetti MN, Guan KL.

Oncogene. 2006 Oct 16;25(48):6347-60. Review.

PMID:
17041621
5.

mTOR and cancer: insights into a complex relationship.

Sabatini DM.

Nat Rev Cancer. 2006 Sep;6(9):729-34. Epub 2006 Aug 17. Review.

PMID:
16915295
6.

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.

7.

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Engelman JA, Luo J, Cantley LC.

Nat Rev Genet. 2006 Aug;7(8):606-19. Review.

PMID:
16847462
8.

Drugging the PI3 kinome.

Workman P, Clarke PA, Guillard S, Raynaud FI.

Nat Biotechnol. 2006 Jul;24(7):794-6. No abstract available. Erratum in: Nat Biotechnol. 2006 Aug;24(8):1033.

PMID:
16841064
9.

Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P, Waterfield M.

Bioorg Med Chem. 2006 Oct 15;14(20):6847-58. Epub 2006 Jul 11.

PMID:
16837202
10.

Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Shaw RJ, Cantley LC.

Nature. 2006 May 25;441(7092):424-30. Review.

PMID:
16724053
11.

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA.

Cancer Cell. 2006 May;9(5):341-9.

12.

PI 3-kinases: hidden potentials revealed.

Vogt PK, Bader AG, Kang S.

Cell Cycle. 2006 May;5(9):946-9. Epub 2006 May 1.

PMID:
16687927
13.

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM.

Cell. 2006 May 19;125(4):733-47. Epub 2006 Apr 27.

14.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N.

Cancer Res. 2006 Feb 1;66(3):1500-8.

15.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

17.

Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C.

Nat Med. 2005 Sep;11(9):936-43. Epub 2005 Aug 28.

18.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

19.

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D.

J Natl Cancer Inst. 2005 Jun 15;97(12):880-7.

PMID:
15956649
20.

PI 3-kinase p110beta: a new target for antithrombotic therapy.

Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH.

Nat Med. 2005 May;11(5):507-14. Epub 2005 Apr 17.

Supplemental Content

Support Center